Biomarker Identification for Bladder Cancer Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02053662|
Recruitment Status : Unknown
Verified April 2017 by Arnab Chakravarti, Ohio State University Comprehensive Cancer Center.
Recruitment status was: Recruiting
First Posted : February 4, 2014
Last Update Posted : April 13, 2017
|Condition or disease||Intervention/treatment|
|Bladder Cancer||Procedure: Sample Collection|
|Study Type :||Observational|
|Estimated Enrollment :||179 participants|
|Official Title:||Biomarker Identification for Bladder Cancer Patients|
|Actual Study Start Date :||January 21, 2014|
|Estimated Primary Completion Date :||November 30, 2018|
|Estimated Study Completion Date :||November 30, 2018|
Bladder Cancer Patients
Patients with muscle invasive bladder cancer. A sample collection of donated cancer and normal adjacent tissues, blood and urine which will be prospectively obtained from patients through the Tissue Procurement Shared Resources (TPSR) and The Ohio State University Comprehensive Cancer Center Biospecimen and Biorepository Resource (BBR) as needed.
Procedure: Sample Collection
A collection of donated cancer and normal adjacent tissues, blood and urine which will be prospectively obtained from patients through the Tissue Procurement Shared Resources (TPSR) and The Ohio State University Comprehensive Cancer Center Biospecimen and Biorepository Resource (BBR) as needed.
- Identify novel biomarkers for bladder cancer [ Time Frame: up to 5 years ]Predict and detect bladder cancer recurrence, specifically through development of biomarkers using bladder cancer tissue samples as well as blood and urine samples. Detect the recurrence of disease through development of blood and urine biomarkers using pre-therapy and post-therapy biospecimens.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02053662
|Contact: Ohio State University Comprehensive Cancer Center||1-800-293-5066||Jamesline@osumc.edu|
|United States, Ohio|
|The Ohio State University Comprehensive Cancer Center||Recruiting|
|Columbus, Ohio, United States, 43210|
|Contact: The Ohio State University Comprehensive Cancer Center 800-293-5066 Jamesline@osumc.edu|
|Contact: Arnab Chakavarti, MD 614-293-8415 Arnab.Chakravarti@osumc.edu|
|Sub-Investigator: Tim Lautenschlaeger, MD|
|Sub-Investigator: Douglas Martin, MD|
|Sub-Investigator: Ahmad Shabsigh, MD|
|Sub-Investigator: Kamal Pohar, MD|
|Sub-Investigator: Steven Clinton, MD|
|Sub-Investigator: Amir Mortazavi, MD|
|Sub-Investigator: Debra Zynger, MD|
|Principal Investigator:||Arna Chakravarti, MD||The Ohio State University Cancer Center|